Vitiligo treatment update
BS Daniel, R Wittal - Australasian Journal of Dermatology, 2015 - Wiley Online Library
Vitiligo treatment update - Daniel - 2015 - Australasian Journal of Dermatology - Wiley Online
Library Skip to Article Content Skip to Article Information Wiley Online Library Wiley Online …
Library Skip to Article Content Skip to Article Information Wiley Online Library Wiley Online …
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial
Importance Narrowband UV-B (NB–UV-B) phototherapy is used extensively to treat vitiligo.
Afamelanotide, an analogue of α–melanocyte-stimulating hormone, is known to induce …
Afamelanotide, an analogue of α–melanocyte-stimulating hormone, is known to induce …
[HTML][HTML] Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients
C Regazzetti, F Joly, C Marty, M Rivier, B Mehul… - Journal of Investigative …, 2015 - Elsevier
Vitiligo affects 1% of the worldwide population. Halting disease progression and
repigmenting the lesional skin represent the two faces of therapeutic challenge in vitiligo …
repigmenting the lesional skin represent the two faces of therapeutic challenge in vitiligo …
[HTML][HTML] Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo–controlled study
M Cavalié, K Ezzedine, E Fontas, H Montaudié… - Journal of Investigative …, 2015 - Elsevier
The risk of relapse after successful repigmentation in vitiligo is estimated to 40% within the
first year. It has been shown in atopic dermatitis that continuous low-level use of topical …
first year. It has been shown in atopic dermatitis that continuous low-level use of topical …
The safety and efficacy of narrow band ultraviolet B treatment in dermatology: a review
Narrow-band ultraviolet B (NBUVB) phototherapy is an important treatment modality in
dermatology. The most common dermatological indications for NBUVB include psoriasis …
dermatology. The most common dermatological indications for NBUVB include psoriasis …
Living with vitiligo: results from a national survey indicate differences between skin phototypes
K Ezzedine, PE Grimes, JM Meurant… - British Journal of …, 2015 - academic.oup.com
DEAR EDITOR, Vitiligo, an acquired, idiopathic skin disease characterized by a generally
progressive loss of inherited skin colour, has an estimated worldwide prevalence of 045 …
progressive loss of inherited skin colour, has an estimated worldwide prevalence of 045 …
Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo
L Komen, V Da Graça, A Wolkerstorfer… - British Journal of …, 2015 - academic.oup.com
Background Vitiligo is a common skin disorder causing depigmented macules that can
impair a patient's quality of life. Currently, there are no standardized outcome measures to …
impair a patient's quality of life. Currently, there are no standardized outcome measures to …
Laser (755 nm) and cryotherapy as depigmentation treatments for vitiligo: a comparative study
N van Geel, L Depaepe… - Journal of the European …, 2015 - Wiley Online Library
Background Depigmentation therapy can be an option in adults with extensive and
refractory vitiligo. Remaining pigmented patches can be removed using depigmentation …
refractory vitiligo. Remaining pigmented patches can be removed using depigmentation …
Correlation of serum thyroid hormones autoantibodies with self-reported exposure to thyroid disruptors in a group of nonsegmental vitiligo patients
Vitiligo is a pigmentary disorder strongly associated with autoimmune thyroid disorders
(ATD). Thyroid hormones antibodies (THAb) directed toward thyroxine (T3) and …
(ATD). Thyroid hormones antibodies (THAb) directed toward thyroxine (T3) and …
Current management of pediatric vitiligo
F Van Driessche, N Silverberg - Pediatric Drugs, 2015 - Springer
Vitiligo is a common inflammatory disorder with worldwide prevalence of 0.4–2% of the
population, with half of cases beginning in childhood. The management of childhood vitiligo …
population, with half of cases beginning in childhood. The management of childhood vitiligo …